Abstract 40: Persistence but not antitumor efficacy of CAR-engineered lymphocytes is governed by a FAS/FAS ligand auto-regulatory circuit

Authors: Fei Yi, Tal Cohen, Paul Zumbo, Razan Eltilib, Hannah Arkin, Michael Gormally, Christopher S. Hackett, Korbinian Kropp, Smita Chandran, Jae H. Park, Doron Betel, Christopher A. Klebanoff

Published: 2024-03-22

DOI: 10.1158/1538-7445.am2024-40

Source: Full article